BioLife Solutions, Inc. Deferred Federal Income Tax Expense (Benefit)
BioLife Solutions, Inc. (BLFS) reported Deferred Federal Income Tax Expense (Benefit) of -$62.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2024-02-29
- BioLife Solutions, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was -$62.00K.
- BioLife Solutions, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was -$2.92M.
- BioLife Solutions, Inc. deferred federal income tax expense (benefit) for fiscal 2021 was -$17.70M.
- BioLife Solutions, Inc. deferred federal income tax expense (benefit) for fiscal 2020 was -$3.30M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2023-12-31 | -$62.00K 10-K · filed 2024-02-29 |
| 2022-12-31 | -$2.92M 10-K · filed 2024-02-29 |
| 2021-12-31 | -$17.70M 10-K · filed 2024-02-29 |
| 2020-12-31 | -$3.30M 10-K · filed 2023-03-31 |
| 2019-12-31 | -$1.54M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |